Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14302725 | 0.84 | ALDH1A1 (0.32) | LOXL2 | |
| SCHEMBL16679797 | 0.81 | MAOA (0.37) | MAOBMAOAIDO1ERN1KMT2A | |
| SCHEMBL25368195 | 0.79 | CYP4F2 (0.44) | MAOBMAOAERN1KMT2A | |
| SCHEMBL30511602 | 0.79 | CYP4F2 (0.44) | MAOBMAOAERN1KMT2A | |
| SCHEMBL43006 | 0.77 | LOXL2 (0.52) | LOXL2MAOBIDO1TAAR1 | |
| SCHEMBL6854243 | 0.77 | ERN1 (0.41) | ERN1 | |
| SCHEMBL96269 | 0.77 | ERN1 (0.41) | ERN1 | |
| SCHEMBL29953223 | 0.75 | ENPP2 (0.42) | MAOBMAOA | |
| SCHEMBL27753886 | 0.75 | ALDH1A1 (0.42) | MAOBMAOAIDO1TAAR1ERN1 | |
| SCHEMBL24721706 | 0.75 | ENPP2 (0.42) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | LOXL2 1327/4885MAOB 4128/4885MAOA 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.